Screening of the Possible Risk Factors for Borderline Personality Disorders and Validation of Maclean Instrument

Sponsor
October University for Modern Sciences and Arts (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05831852
Collaborator
(none)
100
1
6
16.5

Study Details

Study Description

Brief Summary

Borderline personality disorder is a mental illness that severely impacts a person's ability to regulate their emotions. This loss of emotional control can increase impulsivity, affect how a person feels about themselves, and negatively impact their relationships with others. In fact, the societal impact of BPDs might be found in emotional suffering, disability and economic burden. In addition in BPD, the suicide rate might be as high as 8-10%. the presence of BPD also interferes with response to treatment of physical and psychiatric comorbidities, such as migraine, HIV, anxiety disorders and substance use disorders. Furthermore, BPD in particular, are associated with high rates of unemployment, absences from work and inefficiency at work, with only 25% of patients suffering from BPD working full time and 40% receiving disability payments. Accordingly, early detection and management would be of great societal and economic impact. Our Study aim is to validate the Arabic version of Maclean Instrument for screening and detection of BPD and and investigate the possible risk factors associated with that disease

Condition or Disease Intervention/Treatment Phase
  • Other: no intervention

Detailed Description

Borderline personality disorder (BPD) is a mental health problem that affects the way you feel about yourself and others, the way you think , difficulty in managing behavior and emotions, self-image issues and a pattern of relationships that are unstable. BPD patients frequently describe their life as unpredictable and stressful. As stated in the Diagnostic and Statistical Manual of Mental Disorders (5th ed.), borderline personality disorder (BPD) is a serious mental illness characterized by a pervasive pattern of instability in interpersonal relationships, self-image and effect, as well as marked impulsivity. This condition arises in early adulthood or adolescence, leading to severe functional impairment and subjective discomfort. Unfortunately, diagnosis and treatment of BPD is often delayed, leading to a less favorable outcome. This is especially true in patients with early onset BPD, in whom the detection and subsequent therapeutic intervention on the disorder is usually further put off. Indeed, in the last two decades, there has been a great sensibilization towards personality disorder (PD)diagnosis in adolescence, reflected in the significant increase in empirical studies regarding this matter, and in the legitimization of adolescent PD diagnosis in psychiatric nomenclature (DSM-5 and ICD-11), as well as in national treatment guidelines in the UK and Australia. Nonetheless, a recent review by Sharp has stressed how scientific evidence and national practice guidelines are yet to penetrate routine clinical care. Indeed, in common clinical practice diagnosis and consequently, treatment of BPD is usually delayed due to underestimation of symptoms and, often, hesitation to diagnose this disorder in younger individuals. BPD is progressively considered a life expectancy formative disorder that exists on a layered continuum of severity. The recent studies for the adults who have BDP disease couldn't find a pharmacological treatment for them. The symptoms treatment with pharmacotherapy is not accurate for the treatment of BDP in adults, the pharmacotherapy should not be used for adolescent BPD. The only study exist is about the using of omega-3 fatty acids and the increase risk of psychosis. Overall, there is no pharmacological treatment for the BDP disease for adults, also the risks of iatrogenic and poly-pharmacy toxicity is high in these young people. The other comorbidities of the disease are treated from the clinical for adolescents, using the pharmacological therapy when needed. Our study aim is to validate the Arabic version of Maclean Instrument for screening and detection of BPD and and investigate the possible risk factors associated that disease thus decreasing the societal and economic burden of that disease

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Ecologic or Community
Time Perspective:
Cross-Sectional
Official Title:
Screening of the Possible Risk Factors for Borderline Personality Disorders Using Validated Arabic Version of Maclean Screening Tool: A Study in the Egyptian University Students "
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
one group

Other: no intervention
no intervention

Outcome Measures

Primary Outcome Measures

  1. validation of Arabic version of Maclean Instrument [6 months]

    detection of reliability and consistency

  2. Detection of Borderline personality disorder Risk factors in Egyptians students [6 months]

    survey

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 28 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • age group (18-28 years old )

  • University students

Exclusion Criteria:
  • less than 18 years old

  • more than 28 years old

Contacts and Locations

Locations

Site City State Country Postal Code
1 October University for modern sciences and arts Giza Egypt

Sponsors and Collaborators

  • October University for Modern Sciences and Arts

Investigators

  • Principal Investigator: sara Eladawy, PhD, MSA university
  • Study Director: mohamed hafez, biostatistician, biomedical informatics medical research institute Alexandria University
  • Study Chair: mohamed emad, biostatistician, biomedical informatics, medical research institute, Alexandria University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sara ElAdawy, lecturer of clinical pharmacy, October University for Modern Sciences and Arts
ClinicalTrials.gov Identifier:
NCT05831852
Other Study ID Numbers:
  • RSPL 2.2
First Posted:
Apr 26, 2023
Last Update Posted:
Apr 27, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sara ElAdawy, lecturer of clinical pharmacy, October University for Modern Sciences and Arts
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2023